Barbara Gayle Duncan
CIK 1353128 · Chief Accounting Officer · last filed 2026-06-23
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
ICPT price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
225 FRANKLIN STREET SUITE 2100
BOSTON, MA 02110
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| AVIR | Director | 92,350 | $4.11 | $379.6K | $0 | 8 | 2026-06-23 |
| HTI | Director | 23,715 | — | — | $0 | 5 | 2026-05-07 |
| OVID | Director | — | $2.54 | — | $0 | 15 | 2026-03-02 |
| Fusion Pharmaceuticals Inc. (FUSN) Delisted | Director | — | $21.55 | — | $0 | 5 | 2024-06-04 |
| Jounce Therapeutics, Inc. (JNCE) Delisted | Director | 0 | $1.88 | $0 | -$256.2K | 10 | 2023-05-04 |
| Adaptimmune Therapeutics PLC (ADAP) Delisted | Director | — | $0.06 | — | $0 | 3 | 2022-07-01 |
| IMMUNOMEDICS INC (IMMU) Delisted | Director | 0 | — | — | $0 | 7 | 2020-10-23 |
| ASND | Director | — | $251.27 | — | $0 | 3 | 2019-07-03 |
| GNMX | Director | 59,524 | $38.07 | $2.27M | $75.0K | 4 | 2018-07-18 |
| INVA | Director | 52,318 | $21.22 | $1.11M | $0 | 2 | 2017-04-24 |
| INTERCEPT PHARMACEUTICALS, INC. (ICPT) Delisted | Chief Accounting Officer | 30,661 | $19.00 | $582.6K | -$6.80M | 25 | 2016-10-05 |
| Aevi Genomic Medicine, LLC (MDGN) Delisted | Director | — | — | — | $0 | 1 | 2016-04-19 |
| Aevi Genomic Medicine, LLC (MDGN.WS) Delisted | Director | — | — | — | $0 | 2 | 2015-08-06 |
Recent Filings · Page 6 of 10
95 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2018-07-18 | GNMX | Grant (A) | — | $0 | EDGAR |
| 2018-06-26 | ASND | Grant (A) | — | $0 | EDGAR |
| 2018-06-21 | Jounce Therapeutics, Inc. (JNCE) Delisted | Grant (A) | — | $0 | EDGAR |
| 2018-06-18 | GNMX | Grant (A) | — | $0 | EDGAR |
| 2018-06-08 | OVID | Grant (A) | — | $0 | EDGAR |
| 2018-03-19 | Jounce Therapeutics, Inc. (JNCE) Delisted | Mixed | — | -$47.8K | EDGAR |
| 2018-01-29 | Jounce Therapeutics, Inc. (JNCE) Delisted | Mixed | — | -$83.2K | EDGAR |
| 2017-10-18 | GNMX | Buy (P) | +59,524 | $75.0K | EDGAR |
| 2017-08-10 | GNMX | Grant (A) | — | $0 | EDGAR |
| 2017-07-03 | ASND | Grant (A) | — | $0 | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.